DOUBLE-BLIND COMPARISON OF A NOVEL INDANONE DIURETIC (MK-196) WITH HYDROCHLOROTHIAZIDE IN THE TREATMENT OF ESSENTIAL HYPERTENSION

被引:6
作者
WILHELMSSON, CE
MOERLIN, C
LUNDJOHANSEN, P
VORBURGER, C
ENENKEL, W
LUTTERBECK, PM
BOLOGNESE, J
CIRILLO, VJ
TEMPERO, KF
机构
[1] ACAD HOSP UPPSALA,DEPT INTERNAL MED,UPPSALA,SWEDEN
[2] UNIV BERGEN,HAUKELAND SYKEHUS,SCH MED,DEPT MED A,N-5014 BERGEN,NORWAY
[3] STADT KRANKENHAUS,MED KLIN,CH-5400 BADEN,SWITZERLAND
[4] MERCK SHARP & DOHME AG,CH-8008 ZURICH,SWITZERLAND
[5] MERCK SHARP & DOHME,RES LABS,DEPT CLIN BIOSTAT,RAHWAY,NJ 07065
[6] MERCK SHARP & DOHME,RES LABS,DEPT CLIN PHARMACOL,RAHWAY,NJ 07065
[7] KRANKENHAUS STADT VIENNA LAINZ,A-1130 VIENNA,AUSTRIA
关键词
D O I
10.1111/j.1365-2125.1979.tb01012.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The antihypertensive effect and tolerability of MK‐196 (10 mg and 15 mg daily) was compared to hydrochlorothiazide (HCT; 50 mg daily) in a 4‐ week multiclinic, double‐blind study involving 42 patients with mild to moderate, essential hypertension. 2 Both doses of MK‐196 were as effective and sometimes more effective than HCT in lowering standing and supine systolic and diastolic blood pressures. 3 HCT consistently brought about significant increases in serum uric acid and significant decreases in serum potassium; both doses of MK‐196 produced similar but less frequent and smaller changes in both of these parameters. 4 Both doses of MK‐196 brought about significant decreases in body weight at Weeks 3 and 4 of drug treatment. 5 Patients taking MK‐196 reported fewer adverse clinical reactions (10 mg = 15%; 15 mg = 13% than those taking HCT (21%). 6 MK‐196 may offer a therapeutic advantage over HCT as an antihypertensive agent for use in the treatment of mild to moderate, essential hypertension. 1979 The British Pharmacological Society
引用
收藏
页码:261 / 266
页数:6
相关论文
共 14 条
[1]  
ARONOFF A, 1961, CAN MED ASSOC J, V84, P1181
[2]  
CURRY P, 1976, LANCET, V2, P231
[3]   THIAZIDE-INDUCED HYPOKALEMIA - ASSOCIATION WITH ACUTE MYOCARDIAL-INFARCTION AND VENTRICULAR-FIBRILLATION [J].
DUKE, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (01) :43-45
[4]  
DZIEWANOWSKA ZE, 1976, CLIN RES, V24, pA253
[5]  
EMMERSON BT, 1977, PURINE METABOLISM MA, V2, P320
[6]  
FANELLI GM, 1977, J PHARMACOL EXP THER, V200, P402
[7]   RELATION OF ELECTROLYTE DISTURBANCES TO CARDIAC-ARRHYTHMIAS [J].
FISCH, C .
CIRCULATION, 1973, 47 (02) :408-418
[8]  
KAUKER ML, 1977, J PHARMACOL EXP THER, V200, P81
[9]  
MCKENZIE R, 1976, P SOC EXP BIOL MED, V153, P202
[10]   EFFECT OF CHLOROTHIAZIDE THERAPY ON SERUM URIC ACID AND URIC ACID EXCRETION [J].
MONROE, KE ;
GRANT, LH ;
SASAHARA, AA ;
LITTMANN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1959, 261 (06) :290-292